Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Lymphoma

  Free Subscription


1 Am J Hematol
5 Blood
1 Exp Cell Res
2 Haematologica
3 Leuk Lymphoma
1 N Engl J Med
1 PLoS One

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Am J Hematol

  1. SIEGEL SE, Advani A, Seibel N, Muffly L, et al
    Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD versus pediatric-inspired regimens.
    Am J Hematol. 2018 Jul 30. doi: 10.1002/ajh.25229.
    PubMed     Text format     Abstract available


  2. EICHENAUER DA, Plutschow A, Schroder L, Fuchs M, et al
    Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group.
    Blood. 2018 Jul 31. pii: blood-2018-02-836437. doi: 10.1182/blood-2018-02-836437
    PubMed     Text format     Abstract available

  3. MARKS LJ, McCarten K, Pei Q, Friedman DL, et al
    Pericardial Effusion in Hodgkin Lymphoma: A Report from the Children's Oncology Group AHOD0031.
    Blood. 2018 Jul 30. pii: blood-2018-02-834465. doi: 10.1182/blood-2018-02-834465
    PubMed     Text format    

  4. SONG TL, Nairismagi ML, Laurensia Y, Lim JQ, et al
    Oncogenic activation of STAT3 pathway drives PD-L1 expression in natural killer/T cell lymphoma.
    Blood. 2018 Jul 27. pii: blood-2018-01-829424. doi: 10.1182/blood-2018-01-829424
    PubMed     Text format     Abstract available

  5. STRAUS DJ, Jung SH, Pitcher B, Kostakoglu L, et al
    CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET.
    Blood. 2018 Jul 26. pii: blood-2018-01-827246. doi: 10.1182/blood-2018-01-827246
    PubMed     Text format     Abstract available

  6. Pro B, Advani R, Brice P, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709-2717.
    Blood. 2018;132:458-459.
    PubMed     Text format    

    Exp Cell Res

  7. CLARK-KNOWLES KV, Dewar-Darch D, Jardine KE, Coulombe J, et al
    Modulating SIRT1 activity variously affects thymic lymphoma development in mice.
    Exp Cell Res. 2018 Jul 27. pii: S0014-4827(18)30593.
    PubMed     Text format     Abstract available


  8. ADAMS HJA, Kwee TC
    Unproven value of end-of-treatment and serial follow-up FDG-PET in primary mediastinal B-cell lymphoma.
    Haematologica. 2018;103:e380-e381.
    PubMed     Text format    

  9. MELANI C, Roschewski M, Wilson WH
    End-of-treatment and serial PET imaging has prognostic value and clinical utility in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R - Response to Adams et al.
    Haematologica. 2018;103:e382.
    PubMed     Text format    

    Leuk Lymphoma

  10. THORP BC, Badoux X
    Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Leuk Lymphoma. 2018;59:311-320.
    PubMed     Text format     Abstract available

  11. GOYAL S, Oak E, Luo J, Cashen AF, et al
    Minimal activity of nanoparticle albumin-bound (nab) paclitaxel in relapsed or refractory lymphomas: results of a phase-I study.
    Leuk Lymphoma. 2018;59:357-362.
    PubMed     Text format     Abstract available

  12. TOMITA N, Yokoyama M, Yamamoto W, Watanabe R, et al
    The standard international prognostic index for predicting the risk of CNS involvement in DLBCL without specific prophylaxis.
    Leuk Lymphoma. 2018;59:97-104.
    PubMed     Text format     Abstract available

    N Engl J Med

  13. Genetics of Diffuse Large B-Cell Lymphoma.
    N Engl J Med. 2018;379:493-494.
    PubMed     Text format    

    PLoS One

  14. CHACHAJ A, Wisniewski J, Rybka J, Butrym A, et al
    Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.
    PLoS One. 2018;13:e0197148.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.